Clinical experience with the Baerveldt glaucoma drainage implant

S. W. Siegner, P. A. Netland, R. C. Urban, A. S. Williams, D. W. Richards, M. A. Latina, James D Brandt

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Purpose: To assess clinical outcomes in patients who were treated with the Baerveldt glaucoma drainage implant. Methods: The authors performed a retrospective multicenter study of 100 patients (103 eyes) with medically uncontrollable glaucomas who underwent a one-stage implantation with either the 200-, 250-, 350-, or 500-mm2 Baerveldt implant. The authors defined surgical success as 5 mmHg less than intraocular pressure less than 22 mmHg without additional glaucoma surgery and without loss of light perception. Results: With a mean follow-up of 13.6 ± 0.9 months (range, 4-37 months), 74 eyes (71.8%) had successful outcomes. Cumulative life-table success rates were 90.3% at 3 months (n = 103), 72.6% at 6 months (n = 84), and 60.3% at 24 months (n = 34). Intraocular pressure (IOP) was reduced from a mean of 38.5 ± 1.4 mmHg with 2.2 ± 0.1 antiglaucoma medications to 15.1 ± 0.8 mmHg (P < 0.0005) with 0.5 ± 0.1 antiglaucoma medications (P < 0.0005). Visual acuity was improved or remained within one line of the preoperative visual acuity in 90 eyes (87.4%). Complications occurred in 74 eyes (71.8%). A significant portion of these complications (45%) was transient, resolving without any intervention. Only 8% were serious sight-threatening complications. The most common complications included shallow anterior chamber or hypotony (32%), choroidal effusion or hemorrhage (20.4%), corneal decompensation or edema (17.5%), hyphema (14.1%), and tube obstruction (12.6%). Conclusion: The Baerveldt implant is effective in lowering the IOP in patients with intractable glaucomas. Hypotony and other complications are common, which also have been reported in other nonvalved glaucoma drainage implants. However, the majority of these complications did not affect surgical outcome.

Original languageEnglish (US)
Pages (from-to)1298-1307
Number of pages10
JournalOphthalmology
Volume102
Issue number9
StatePublished - 1995

Fingerprint

Glaucoma Drainage Implants
Intraocular Pressure
Glaucoma
Visual Acuity
Hyphema
Life Tables
Anterior Chamber
Multicenter Studies
Edema
Retrospective Studies
Hemorrhage
Light

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Siegner, S. W., Netland, P. A., Urban, R. C., Williams, A. S., Richards, D. W., Latina, M. A., & Brandt, J. D. (1995). Clinical experience with the Baerveldt glaucoma drainage implant. Ophthalmology, 102(9), 1298-1307.

Clinical experience with the Baerveldt glaucoma drainage implant. / Siegner, S. W.; Netland, P. A.; Urban, R. C.; Williams, A. S.; Richards, D. W.; Latina, M. A.; Brandt, James D.

In: Ophthalmology, Vol. 102, No. 9, 1995, p. 1298-1307.

Research output: Contribution to journalArticle

Siegner, SW, Netland, PA, Urban, RC, Williams, AS, Richards, DW, Latina, MA & Brandt, JD 1995, 'Clinical experience with the Baerveldt glaucoma drainage implant', Ophthalmology, vol. 102, no. 9, pp. 1298-1307.
Siegner SW, Netland PA, Urban RC, Williams AS, Richards DW, Latina MA et al. Clinical experience with the Baerveldt glaucoma drainage implant. Ophthalmology. 1995;102(9):1298-1307.
Siegner, S. W. ; Netland, P. A. ; Urban, R. C. ; Williams, A. S. ; Richards, D. W. ; Latina, M. A. ; Brandt, James D. / Clinical experience with the Baerveldt glaucoma drainage implant. In: Ophthalmology. 1995 ; Vol. 102, No. 9. pp. 1298-1307.
@article{c33bf35cb10e48bbbffb4ef2af16c556,
title = "Clinical experience with the Baerveldt glaucoma drainage implant",
abstract = "Purpose: To assess clinical outcomes in patients who were treated with the Baerveldt glaucoma drainage implant. Methods: The authors performed a retrospective multicenter study of 100 patients (103 eyes) with medically uncontrollable glaucomas who underwent a one-stage implantation with either the 200-, 250-, 350-, or 500-mm2 Baerveldt implant. The authors defined surgical success as 5 mmHg less than intraocular pressure less than 22 mmHg without additional glaucoma surgery and without loss of light perception. Results: With a mean follow-up of 13.6 ± 0.9 months (range, 4-37 months), 74 eyes (71.8{\%}) had successful outcomes. Cumulative life-table success rates were 90.3{\%} at 3 months (n = 103), 72.6{\%} at 6 months (n = 84), and 60.3{\%} at 24 months (n = 34). Intraocular pressure (IOP) was reduced from a mean of 38.5 ± 1.4 mmHg with 2.2 ± 0.1 antiglaucoma medications to 15.1 ± 0.8 mmHg (P < 0.0005) with 0.5 ± 0.1 antiglaucoma medications (P < 0.0005). Visual acuity was improved or remained within one line of the preoperative visual acuity in 90 eyes (87.4{\%}). Complications occurred in 74 eyes (71.8{\%}). A significant portion of these complications (45{\%}) was transient, resolving without any intervention. Only 8{\%} were serious sight-threatening complications. The most common complications included shallow anterior chamber or hypotony (32{\%}), choroidal effusion or hemorrhage (20.4{\%}), corneal decompensation or edema (17.5{\%}), hyphema (14.1{\%}), and tube obstruction (12.6{\%}). Conclusion: The Baerveldt implant is effective in lowering the IOP in patients with intractable glaucomas. Hypotony and other complications are common, which also have been reported in other nonvalved glaucoma drainage implants. However, the majority of these complications did not affect surgical outcome.",
author = "Siegner, {S. W.} and Netland, {P. A.} and Urban, {R. C.} and Williams, {A. S.} and Richards, {D. W.} and Latina, {M. A.} and Brandt, {James D}",
year = "1995",
language = "English (US)",
volume = "102",
pages = "1298--1307",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Clinical experience with the Baerveldt glaucoma drainage implant

AU - Siegner, S. W.

AU - Netland, P. A.

AU - Urban, R. C.

AU - Williams, A. S.

AU - Richards, D. W.

AU - Latina, M. A.

AU - Brandt, James D

PY - 1995

Y1 - 1995

N2 - Purpose: To assess clinical outcomes in patients who were treated with the Baerveldt glaucoma drainage implant. Methods: The authors performed a retrospective multicenter study of 100 patients (103 eyes) with medically uncontrollable glaucomas who underwent a one-stage implantation with either the 200-, 250-, 350-, or 500-mm2 Baerveldt implant. The authors defined surgical success as 5 mmHg less than intraocular pressure less than 22 mmHg without additional glaucoma surgery and without loss of light perception. Results: With a mean follow-up of 13.6 ± 0.9 months (range, 4-37 months), 74 eyes (71.8%) had successful outcomes. Cumulative life-table success rates were 90.3% at 3 months (n = 103), 72.6% at 6 months (n = 84), and 60.3% at 24 months (n = 34). Intraocular pressure (IOP) was reduced from a mean of 38.5 ± 1.4 mmHg with 2.2 ± 0.1 antiglaucoma medications to 15.1 ± 0.8 mmHg (P < 0.0005) with 0.5 ± 0.1 antiglaucoma medications (P < 0.0005). Visual acuity was improved or remained within one line of the preoperative visual acuity in 90 eyes (87.4%). Complications occurred in 74 eyes (71.8%). A significant portion of these complications (45%) was transient, resolving without any intervention. Only 8% were serious sight-threatening complications. The most common complications included shallow anterior chamber or hypotony (32%), choroidal effusion or hemorrhage (20.4%), corneal decompensation or edema (17.5%), hyphema (14.1%), and tube obstruction (12.6%). Conclusion: The Baerveldt implant is effective in lowering the IOP in patients with intractable glaucomas. Hypotony and other complications are common, which also have been reported in other nonvalved glaucoma drainage implants. However, the majority of these complications did not affect surgical outcome.

AB - Purpose: To assess clinical outcomes in patients who were treated with the Baerveldt glaucoma drainage implant. Methods: The authors performed a retrospective multicenter study of 100 patients (103 eyes) with medically uncontrollable glaucomas who underwent a one-stage implantation with either the 200-, 250-, 350-, or 500-mm2 Baerveldt implant. The authors defined surgical success as 5 mmHg less than intraocular pressure less than 22 mmHg without additional glaucoma surgery and without loss of light perception. Results: With a mean follow-up of 13.6 ± 0.9 months (range, 4-37 months), 74 eyes (71.8%) had successful outcomes. Cumulative life-table success rates were 90.3% at 3 months (n = 103), 72.6% at 6 months (n = 84), and 60.3% at 24 months (n = 34). Intraocular pressure (IOP) was reduced from a mean of 38.5 ± 1.4 mmHg with 2.2 ± 0.1 antiglaucoma medications to 15.1 ± 0.8 mmHg (P < 0.0005) with 0.5 ± 0.1 antiglaucoma medications (P < 0.0005). Visual acuity was improved or remained within one line of the preoperative visual acuity in 90 eyes (87.4%). Complications occurred in 74 eyes (71.8%). A significant portion of these complications (45%) was transient, resolving without any intervention. Only 8% were serious sight-threatening complications. The most common complications included shallow anterior chamber or hypotony (32%), choroidal effusion or hemorrhage (20.4%), corneal decompensation or edema (17.5%), hyphema (14.1%), and tube obstruction (12.6%). Conclusion: The Baerveldt implant is effective in lowering the IOP in patients with intractable glaucomas. Hypotony and other complications are common, which also have been reported in other nonvalved glaucoma drainage implants. However, the majority of these complications did not affect surgical outcome.

UR - http://www.scopus.com/inward/record.url?scp=0029156132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029156132&partnerID=8YFLogxK

M3 - Article

C2 - 9097766

AN - SCOPUS:0029156132

VL - 102

SP - 1298

EP - 1307

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 9

ER -